-
Product Insights
New![]()
Net Present Value Model: Adaptimmune Therapeutics Plc’s AFP
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
AFP – Lubbock Food Manufacturing Facility Expansion – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our AFP - Lubbock Food Manufacturing Facility Expansion - Texas report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADPA-2AFP in Hepatocellular Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADPA-2AFP in Hepatocellular Carcinoma Drug Details: ADPA-2AFP is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACT-101 in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ACT-101 in Ulcerative Colitis Drug Details:ACT-101 is under development for the treatment of myasthenia gravis, multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACT-101 in Hashimoto Thyroiditis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ACT-101 in Hashimoto ThyroiditisDrug Details:ACT-101 is under development for the treatment of myasthenia gravis, multiple sclerosis,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Metastatic Adenocarcinoma of The Pancreas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Metastatic Adenocarcinoma of The Pancreas Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Esophageal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Esophageal Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Bladder Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: Ramucirumab (Cyramza) is an antineoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Gallbladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Gallbladder Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Squamous Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Squamous Non-Small Cell Lung Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Urethral Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Urethral Cancer Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Non-Small Cell Lung Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Non-Small Cell Lung Carcinoma Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ramucirumab in Thymic Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ramucirumab in Thymic Carcinoma Drug Details: Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated...
-
Sector Analysis
Prenatal Screening Market Size by Segments, Share, Regulatory and Reimbursement, Procedures and Forecast to 2033
Prenatal Screening Market Report Overview The prenatal screening market size was valued at $642.3 million in 2022. In most countries, maternal serum screening and ultrasound remain standard-of-care for screening of pregnant women for chromosome aneuploidies and other birth defects. If these tests are positive, then prenatal diagnosis is typically performed via either amniocentesis or chorionic villus sampling (CVS). However, both amniocentesis and CVS are invasive techniques that have a risk of fetal death and miscarriage. NIPT is performed using cell-free...
-
Company Profile
![]()
Adaptimmune Ltd – Company Profile
Adaptimmune Ltd (Adaptimmune), a subsidiary of Adaptimmune Therapeutics plc is a biopharmaceutical company. The company is engaged in developing T-cell receptors for T-cell therapy and SPEAR TCR therapies to utilize the body’s immune system by engineering the naturally occurring T-cells. Adaptimmune’s product pipeline include ADP-A2M10 (MAGE-A10) for melanoma, urothelial cancer, ADP-A2M4 (MAGE-A4) for synovial sarcoma, myxoid cell liposarcoma, ovarian cancer, ADP-A2AFP (AFP) for liver cancer. Its clinical trials include multiple myeloma trial, synovial sarcoma trial, ovarian cancer trial, non-small cell...
Add to Basket -
Company Profile
![]()
Credicorp Ltd – Company Profile
Credicorp Ltd (Credicorp) is a financial services holding company, offering financial solutions such as banking including commercial and investment banking, insurance including property and casualty, and life and health insurance, pension funds including private pension fund management, and brokerage services including trust, custody and securitization services, asset management and proprietary trading and investment, through its subsidiaries. Its principal operating subsidiaries include Banco de Credito del Peru, Atlantic Security Bank, Pacifico Compania de Seguros y Reaseguros, Prima AFP SA, Credicorp Capital...
Add to Basket -
Product Insights
![]()
Net Present Value Model: AFP
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AFP Drug Details ADPA-2AFP is under...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADPA-2AFP
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ADPA-2AFP Drug Details ADPA-2AFP is under development for the treatment of hepatocellular carcinoma. It...
-
Product Insights
![]()
Net Present Value Model: Cyramza
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Cyramza Drug Details Ramucirumab (Cyramza) is...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.